Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab + lenalidomide versus daratumumab + lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
2024-517325-43-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing Elranatamab + lenalidomide with Daratumumab + lenalidomide (2 arms). Primary endpoint: MRD negativity at 1 year. Planned start Mar 2025; status: authorised.
02
Drugs
elranatamabdaratumumablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517325-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517325-43-00.